epoprostenol

Summary

Summary: A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY).

Top Publications

  1. ncbi Health-related quality of life in patients with pulmonary arterial hypertension
    Shirin Shafazand
    The George Washington University, Washington Hospital Center, Washington, DC, USA
    Chest 126:1452-9. 2004
  2. pmc Treprostinil increases the number and angiogenic potential of endothelial progenitor cells in children with pulmonary hypertension
    David M Smadja
    Universite Paris Descartes, Paris, France
    Angiogenesis 14:17-27. 2011
  3. ncbi High levels of nitric oxide in individuals with pulmonary hypertension receiving epoprostenol therapy
    M Ozkan
    Departments of Pulmonary and Critical Care Medicine, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Lung 179:233-43. 2001
  4. ncbi Involvement of cyclo-oxygenase-1-mediated prostacyclin synthesis in the vasoconstrictor activity evoked by ACh in mouse arteries
    Bin Liu
    Cardiovascular Research Center, Shantou University College of Medicine, 22 Xin Ling Road, Shantou, China 515041
    Exp Physiol 97:277-89. 2012
  5. ncbi Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial
    Victor F Tapson
    Division of Pulmonary and Critical Care Medicine, Room 351 Bell Building, Duke University Medical Center, Durham, NC 27710, USA
    Chest 129:683-8. 2006
  6. ncbi Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil
    R J Barst
    Columbia University College of Physicians and Surgeons, 3959 Broadway, BHN 2 255, New York, NY 10032, USA
    Eur Respir J 28:1195-203. 2006
  7. ncbi Angiogenesis induced by CNS inflammation promotes neuronal remodeling through vessel-derived prostacyclin
    Rieko Muramatsu
    Department of Molecular Neuroscience, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
    Nat Med 18:1658-64. 2012
  8. ncbi Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial
    Vallerie V McLaughlin
    University of Michigan Health System, CVC Cardiovascular Medicine, Ann Arbor, Michigan 48109 5853, USA
    J Am Coll Cardiol 55:1915-22. 2010
  9. ncbi Prostaglandin I2 mediates contraction and relaxation of vascular smooth muscle
    S P Williams
    Department of Pharmacology and Cell Biophysics, University of Cincinnati College of Medicine, Ohio
    Am J Physiol 267:H796-803. 1994
  10. ncbi Selective augmentation of prostacyclin production by combined prostacyclin synthase and cyclooxygenase-1 gene transfer
    S K Shyue
    Vascular Biology Program, Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan
    Circulation 103:2090-5. 2001

Research Grants

Detail Information

Publications305 found, 100 shown here

  1. ncbi Health-related quality of life in patients with pulmonary arterial hypertension
    Shirin Shafazand
    The George Washington University, Washington Hospital Center, Washington, DC, USA
    Chest 126:1452-9. 2004
    ..This study describes HRQOL in a cohort of patients with PAH...
  2. pmc Treprostinil increases the number and angiogenic potential of endothelial progenitor cells in children with pulmonary hypertension
    David M Smadja
    Universite Paris Descartes, Paris, France
    Angiogenesis 14:17-27. 2011
    ..In the present study, objectives were to determine whether EPC may contribute to vasodilator treatment efficacy in PAH...
  3. ncbi High levels of nitric oxide in individuals with pulmonary hypertension receiving epoprostenol therapy
    M Ozkan
    Departments of Pulmonary and Critical Care Medicine, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Lung 179:233-43. 2001
    ..with PPH and secondary pulmonary hypertension (SPH) on various therapies, including the potent vasodilator epoprostenol (prostacyclin), compared with healthy controls...
  4. ncbi Involvement of cyclo-oxygenase-1-mediated prostacyclin synthesis in the vasoconstrictor activity evoked by ACh in mouse arteries
    Bin Liu
    Cardiovascular Research Center, Shantou University College of Medicine, 22 Xin Ling Road, Shantou, China 515041
    Exp Physiol 97:277-89. 2012
    ....
  5. ncbi Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial
    Victor F Tapson
    Division of Pulmonary and Critical Care Medicine, Room 351 Bell Building, Duke University Medical Center, Durham, NC 27710, USA
    Chest 129:683-8. 2006
    Pulmonary arterial hypertension (PAH) is a life-threatening disease for which both continuous IV epoprostenol and continuous subcutaneous treprostinil have proven effective...
  6. ncbi Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil
    R J Barst
    Columbia University College of Physicians and Surgeons, 3959 Broadway, BHN 2 255, New York, NY 10032, USA
    Eur Respir J 28:1195-203. 2006
    Pulmonary arterial hypertension (PAH) is fatal if untreated. Intravenous epoprostenol improves exercise capacity and haemodynamics in PAH, and increases survival in idiopathic PAH (IPAH)...
  7. ncbi Angiogenesis induced by CNS inflammation promotes neuronal remodeling through vessel-derived prostacyclin
    Rieko Muramatsu
    Department of Molecular Neuroscience, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
    Nat Med 18:1658-64. 2012
    ..These findings reveal an important function of angiogenesis in neuronal rewiring and suggest that prostacyclin is a promising molecule for enhancing functional recovery from CNS disease...
  8. ncbi Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial
    Vallerie V McLaughlin
    University of Michigan Health System, CVC Cardiovascular Medicine, Ann Arbor, Michigan 48109 5853, USA
    J Am Coll Cardiol 55:1915-22. 2010
    ..This study assessed the efficacy and safety of inhaled treprostinil in pulmonary arterial hypertension (PAH) patients receiving therapy with either bosentan or sildenafil...
  9. ncbi Prostaglandin I2 mediates contraction and relaxation of vascular smooth muscle
    S P Williams
    Department of Pharmacology and Cell Biophysics, University of Cincinnati College of Medicine, Ohio
    Am J Physiol 267:H796-803. 1994
    ..0 and 2.3 microM, respectively. These results suggest that 1) PGI2 induces relaxation through a PGI2-PGE1 receptor, and 2) higher concentrations of PGI2 act at the TxA2-PGH2 receptor to decrease PGI2-induced relaxation...
  10. ncbi Selective augmentation of prostacyclin production by combined prostacyclin synthase and cyclooxygenase-1 gene transfer
    S K Shyue
    Vascular Biology Program, Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan
    Circulation 103:2090-5. 2001
    ..Combined COX-1 and PGIS gene transfer has the potential for therapeutic augmentation of prostacyclin...
  11. ncbi Cyclooxygenase-2 expression, prostacyclin production and endothelial protection of high-density lipoprotein
    Donghui Liu
    The Institute of Cardiovascular Sciences, Ministry of Education, Peking University Health Science Center, Haidian District, Beijing, China
    Cardiovasc Hematol Disord Drug Targets 12:98-105. 2012
    ....
  12. ncbi Induction of prostacyclin/PGI2 synthase expression after cerebral ischemia-reperfusion
    Yao Ching Fang
    Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan, ROC
    J Cereb Blood Flow Metab 26:491-501. 2006
    ..These findings indicate that PGIS protects the brain by enhancing PGI2 synthesis and creating a favorable PGI2/TXA2 ratio...
  13. ncbi Living with pulmonary artery hypertension: patients' experiences
    Maureen P Flattery
    Cardiopulmonary Transplant Program, Richmond, Virginia 23298, USA
    Heart Lung 34:99-107. 2005
    ..Little investigation has been done on the impact of living with PAH despite inferences that quality of life (QOL) improves...
  14. ncbi Cyclooxygenase-2-derived prostacyclin regulates arterial thrombus formation by suppressing tissue factor in a sirtuin-1-dependent-manner
    Silvia S Barbieri
    Centro Cardiologico Monzino, IRCCS, Via Parea 4, 20138 Milano, Italy
    Circulation 126:1373-84. 2012
    ..Selective inhibitors of cyclooxygenase (COX)-2 increase the risk of myocardial infarction and thrombotic events, but the responsible mechanisms are not fully understood...
  15. ncbi Sphingosine-1-phosphate: A bioactive lipid that confers high-density lipoprotein with vasculoprotection mediated by nitric oxide and prostacyclin
    Cristina Rodriguez
    Centro de Investigacion Cardiovascular CSIC ICCC, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
    Thromb Haemost 101:665-73. 2009
    ....
  16. ncbi Effects of epoprostenol on right ventricular hypertrophy and dilatation in pulmonary hypertension
    Roald J Roeleveld
    Department of Pulmonology, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
    Chest 125:572-9. 2004
    To gain more knowledge of changes in main pulmonary artery flow and right ventricular mass and volumes in patients with pulmonary hypertension during epoprostenol therapy.
  17. ncbi Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival
    Olivier Sitbon
    Service de Pneumologie et Reanimation, UPRES EA 2705 on Pulmonary Vascular Diseases, Hopital Antoine Beclere, Universite Paris Sud, Clamart, France
    J Am Coll Cardiol 40:780-8. 2002
    We sought to determine the factors associated with long-term survival in patients with primary pulmonary hypertension (PPH) treated with continuous epoprostenol infusion.
  18. ncbi Protective effect of beraprost sodium, a stable prostacyclin analog, in the development of cigarette smoke extract-induced emphysema
    Yan Chen
    First Department of Medicine, Shinshu University School of Medicine, 3 1 1 Asahi, Matsumoto 390 8621, Japan
    Am J Physiol Lung Cell Mol Physiol 296:L648-56. 2009
    ..BPS may potentially represent a new therapeutic option in the prevention of emphysema in humans in prospect...
  19. pmc Updated evidence-based treatment algorithm in pulmonary arterial hypertension
    Robyn J Barst
    Columbia University, New York, New York 10583, USA
    J Am Coll Cardiol 54:S78-84. 2009
    ..Continuous intravenous administration of epoprostenol remains the treatment of choice in WHO functional class IV patients...
  20. ncbi Peroxynitrite and vascular endothelial dysfunction in diabetes mellitus
    Ming Hui Zou
    Vascular Research Laboratory, Graduate School of Medicine, University of Tennessee, Knoxville, TN 37920, USA
    Endothelium 11:89-97. 2004
    ..The authors' studies indicate that in diabetes the synthetic enzymes of the two major endogenous vasodilators undergo oxidative inactivation by different mechanisms, which are, however, tightly interdependent...
  21. pmc Prostacyclin-IP signaling and prostaglandin E2-EP2/EP4 signaling both mediate joint inflammation in mouse collagen-induced arthritis
    Tetsuya Honda
    Department of Pharmacology, Faculty of Medicine, Kyoto University, Kyoto 606 8501, Japan
    J Exp Med 203:325-35. 2006
    ..Our results show significant roles of both PGI2-IP and PGE2-EP2/EP4 signaling in the development of CIA, and suggest that inhibition of PGE2 synthesis alone may not be sufficient for suppression of RA symptoms...
  22. ncbi Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial
    Jagdish Hiremath
    Ruby Hall Clinic, Pune, India
    J Heart Lung Transplant 29:137-49. 2010
    ..Pulmonary arterial hypertension (PAH) remains a poorly understood and frequently lethal disease with few treatment options...
  23. ncbi Increased bone mass in adult prostacyclin-deficient mice
    Chalida Nakalekha
    Department of Cellular Physiological Chemistry, Tokyo Medical and Dental University, Bunkyo ku, Tokyo 113 8549, Japan
    J Endocrinol 204:125-33. 2010
    ..Our findings demonstrate for the first time that PGI(2) is involved in bone metabolism in vivo...
  24. ncbi COX-2 inhibitors and cardiovascular risk
    Colin D Funk
    Department of Biochemistry, Queen s University, Kingston, Ontario, Canada
    J Cardiovasc Pharmacol 50:470-9. 2007
    ..This review discusses the background to our current understanding of coxibs and provides further information relating to recent mechanistic insights into how COX-2 inhibition promotes cardiovascular risk...
  25. ncbi Dose proportionality of treprostinil sodium administered by continuous subcutaneous and intravenous infusion
    C Shane McSwain
    Clinical Affairs, United Therapeutics Corporation, One Park Drive, 4th Floor, Research Triangle Park, NC 27709, USA
    J Clin Pharmacol 48:19-25. 2008
    ..941 (95% confidence interval: 0.809-1.073). This study supports previous findings of linearity at lower doses up to 15 ng/kg/min and demonstrates linearity at treprostinil doses up to 125 ng/kg/min...
  26. ncbi Evaluation of disease-specific health-related quality of life in patients with pulmonary arterial hypertension
    Michael Zlupko
    Pulmonary, Allergy and Critical Care Division, Department of Medicine, University of Pennsylvania School of Medicine, Penn Presbyterian Medical Center, Suite 120, 51 North 39th Street, Philadelphia, PA 19104, USA
    Respir Med 102:1431-8. 2008
    ..The Minnesota Living with Heart Failure questionnaire was recently adapted and validated for HRQOL measurement in PAH. We applied this pulmonary hypertension-specific version (MLHF-PH) to a larger population of PAH patients...
  27. ncbi An outcome study of severe traumatic head injury using the "Lund therapy" with low-dose prostacyclin
    S Naredi
    Department of Anaesthesia and Intensive Care, Umea University Hospital, Sweden
    Acta Anaesthesiol Scand 45:402-6. 2001
    ..The present clinical outcome study aims at evaluating whether the previously obtained good outcome with the Lund therapy can be reproduced, and whether the addition of prostacyclin has any adverse side-effects...
  28. ncbi Pulmonary arterial hypertension: pathobiology, diagnosis, treatment, and emerging therapies
    Warren D Rosenblum
    Division of Cardiology, Department of Medicine, New York Medical College Westchester Medical Center, Valhalla, NY 10595, USA
    Cardiol Rev 18:58-63. 2010
    ..Although much needs to be learned, this review will discuss our current knowledge, results of clinical trials, along with treatment options and emerging therapies available for the treatment of this disorder...
  29. ncbi Regulation of TNFalpha and interleukin-10 production by prostaglandins I(2) and E(2): studies with prostaglandin receptor-deficient mice and prostaglandin E-receptor subtype-selective synthetic agonists
    S Shinomiya
    Department of Pharmacology, School of Pharmaceutical Sciences, Kitasato University, 5 9 1 Shirokane, Minato ku, Tokyo 108 8641, Japan
    Biochem Pharmacol 61:1153-60. 2001
    ..Thus the results suggest that PGI(2) and PGE(2) generated simultaneously with cytokines by macrophages treated with zymosan may influence the cytokine production through IP, EP2, and EP4 receptors...
  30. ncbi Prostacyclin and its analogues in the treatment of pulmonary hypertension
    Horst Olschewski
    Medical Clinic II, Klinikstrasse 36, D 35392 Giessen, Germany
    Pharmacol Ther 102:139-53. 2004
    ..It remains to be determined which patients will profit most from which substance (or combination) and mode of application...
  31. pmc Acyl chain-dependent effect of lysophosphatidylcholine on endothelial prostacyclin production
    Monika Riederer
    Institute of Molecular Biology and Biochemistry, University of Helsinki, Helsinki, Finland
    J Lipid Res 51:2957-66. 2010
    ....
  32. ncbi Cyclooxygenase-2-derived endogenous prostacyclin enhances mouse embryo hatching
    Jaou Chen Huang
    Department of Obstetrics and Gynecology, University of Texas Health Science Center Houston, Houston, TX 77030, USA
    Hum Reprod 19:2900-6. 2004
    ..The role of prostaglandins (PGs) in embryo hatching remains controversial. In addition, there is no direct evidence that mouse embryos synthesize PGs...
  33. ncbi Stimulation of embryo hatching and implantation by prostacyclin and peroxisome proliferator-activated receptor delta activation: implication in IVF
    J C Huang
    Department of Obstetrics, Gynecology and Reproductive Services, The University of Texas Health Science Center, Houston, TX 77030, USA
    Hum Reprod 22:807-14. 2007
    ..The mechanism underlying the effects of PGI(2) is unclear. It has been reported that peroxisome proliferator-activated receptor delta (PPARdelta) mediates the effects of PGI(2) at the implantation sites...
  34. ncbi COX-2-derived prostacyclin confers atheroprotection on female mice
    Karine M Egan
    Institute for Translational Medicine and Therapeutics, University of Pennsylvania, PA 19104, USA
    Science 306:1954-7. 2004
    ..This suggests that chronic treatment of patients with selective inhibitors of COX-2 could undermine protection from cardiovascular disease in premenopausal females...
  35. pmc PGI2 as a regulator of CD4+ subset differentiation and function
    Madison G Boswell
    Division of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA
    Prostaglandins Other Lipid Mediat 96:21-6. 2011
    ..In contrast, PGI(2) seems to enhance Th17-favoring polarization conditions, resulting in Th17 cytokine production. Therefore, PGI(2) may either promote or inhibit individual CD4+ cell subsets and impact adaptive immune responses...
  36. ncbi Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial
    Gerald Simonneau
    Division of Pulmonary and Critical Care Medicine, Antoine Beclere Hospital, Clamart, Paris Sud University, Clamart, France
    Am J Respir Crit Care Med 165:800-4. 2002
    ..We conclude that chronic subcutaneous infusion of treprostinil is an effective treatment with an acceptable safety profile in patients with pulmonary arterial hypertension...
  37. pmc Hypoxia upregulates PGI-synthase and increases PGI₂ release in human vascular cells exposed to inflammatory stimuli
    Mercedes Camacho
    Angiology, Vascular Biology, and Inflammation Laboratory, Institute of Biomedical Research IIB Sant Pau, Barcelona, Spain
    J Lipid Res 52:720-31. 2011
    ..These data suggest that PGIS upregulation is part of the adaptive response of vascular cells to hypoxic stress and could play a role in counteracting the deleterious effect of inflammatory stimuli...
  38. ncbi Beraprost sodium regulates cell cycle in vascular smooth muscle cells through cAMP signaling by preventing down-regulation of p27(Kip1)
    M Ii
    First Department of Internal Medicine, Osaka Medical College, 2 7 Daigaku machi, Takatsuki, 569 8686, Osaka, Japan
    Cardiovasc Res 52:500-8. 2001
    ..Furthermore, we determined its anti-atherosclerotic effects in cultured smooth muscle cells (SMCs)...
  39. ncbi Prostaglandin I2 promotes recruitment of endothelial progenitor cells and limits vascular remodeling
    Jun ichi Kawabe
    Department of Pharmacology, Asahikawa Medical College, Midorigaoka Higashi 2 1 1 1, Asahikawa 078 8510, Japan
    Arterioscler Thromb Vasc Biol 30:464-70. 2010
    ..We evaluated whether prostaglandin I(2) plays a role in the regulation of the function of EPCs to limit vascular remodeling...
  40. ncbi Prostacyclin attenuates oxidative damage of myocytes by opening mitochondrial ATP-sensitive K+ channels via the EP3 receptor
    Ken Shinmura
    Department of Internal Medicine, Keio University School of Medicine, Shinanomachi, Tokyo, Japan
    Am J Physiol Heart Circ Physiol 288:H2093-101. 2005
    ..The data also indicate that activation of EP3 receptors primes the opening of mitochondrial K(ATP) channels and that this mechanism is essential for EP3-dependent protection...
  41. ncbi Hemodynamics and epoprostenol use are associated with thrombocytopenia in pulmonary arterial hypertension
    Kelly M Chin
    Department of Internal Medicine, University of Texas Southwestern Pulmonary Hypertension Program, Dallas, TX 75235 9254, USA
    Chest 135:130-6. 2009
    ..Thrombocytopenia develops in some patients with advanced pulmonary arterial hypertension (PAH) while receiving IV epoprostenol therapy...
  42. ncbi Segmental cerebral vasoconstriction: successful treatment of secondary cerebral ischaemia with intravenous prostacyclin
    Per Olof Grände
    Department of Anaesthesiology and Intensive Care, Lund University and Lund University Hospital, Lund, Sweden
    Cephalalgia 30:890-5. 2010
    ..Although not fully compatible, our case had several clinical characteristics and radiological findings reminiscent of those of the 'segmental reversible vasoconstriction syndrome', sometimes called the Call-Fleming syndrome...
  43. ncbi Epoprostenol therapy decreases elevated circulating levels of monocyte chemoattractant protein-1 in patients with primary pulmonary hypertension
    Hashimoto Katsushi
    Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine and Dentistry, Japan
    Circ J 68:227-31. 2004
    ..Monocyte chemoattractant protein-1 (MCP-1) is recognized as a potent chemotactic and activating factor for monocytes and leukocytes, but its significance in PPH is unclear...
  44. ncbi Transesophageal echocardiographic diagnosis of carbon dioxide embolism during minimally invasive saphenous vein harvesting and treatment with inhaled epoprostenol
    Andre Martineau
    Department of Anesthesiology, Montreal Heart Institute, 5000 Belanger Street East, Montreal, Quebec, H1T 1C8 Canada
    Anesth Analg 96:962-4, table of contents. 2003
    ..Transesophageal echocardiography was useful in the diagnosis of CO2 embolism and to assess response to inhaled epoprostenol.
  45. ncbi Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers
    Kevin Laliberte
    United Therapeutics Corporation, Research Triangle Park, North Carolina 27709, USA
    J Cardiovasc Pharmacol 44:209-14. 2004
    ..4 and 4.6 hours following intravenous and subcutaneous administration, respectively. Based on these findings it was concluded that intravenously and subcutaneously administered treprostinil are bioequivalent at steady state...
  46. ncbi Impact of stable PGI₂ analog iloprost on early graft viability after liver transplantation: a pilot study
    Erik Bärthel
    Department of General, Visceral and Vascular Surgery, Friedrich Schiller University, Jena, Germany
    Clin Transplant 26:E38-47. 2012
    ..The aim of this study was to analyze the effect of the continuously administered prostaglandin I(2) analog iloprost on allograft function after LT...
  47. pmc Prostacyclin in the intensive care setting
    D Dunbar Ivy
    Department of Pediatrics, University of Colorado Denver School of Medicine, The Children s Hospital, Aurora, CO, USA
    Pediatr Crit Care Med 11:S41-5. 2010
    ..Three prostanoids have been developed to treat PAH: epoprostenol, treprostinil, and iloprost...
  48. pmc Characterization of the prostanoid receptor(s) on human blood monocytes at which prostaglandin E2 inhibits lipopolysaccharide-induced tumour necrosis factor-alpha generation
    K K Meja
    Imperial College School of Medicine, National Heart and Lung Institute, London
    Br J Pharmacol 122:149-57. 1997
    ..Given the pharmacological behaviour of butaprost, AH 6809 and AH 23848B in these cells, we propose that multiple (EP2- and/or EP-4- and/or i.p.) or novel EP-receptors mediate the inhibitory effect of PGE2 on TNF alpha generation...
  49. ncbi Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation
    Y F Chen
    Public Health, Epidemiology and Biostatistics, School of Health and Population Sciences, University of Birmingham, UK
    Health Technol Assess 13:1-320. 2009
    To investigate the clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for the treatment of adults with pulmonary arterial hypertension (PAH) within their licensed indications.
  50. ncbi Prostacyclin antagonism reduces pain and inflammation in rodent models of hyperalgesia and chronic arthritis
    Anne Marie Pulichino
    Merck Frosst Centre for Therapeutic Research, Kirkland, Quebec, Canada
    J Pharmacol Exp Ther 319:1043-50. 2006
    ..The results also suggest that the inhibition of PGI(2) synthesis by NSAIDs and COX-2 inhibitors, in addition to that of PGE(2), contributes to their efficacy in treating the signs of arthritis...
  51. ncbi Prostacyclin treatment in severe traumatic brain injury: a microdialysis and outcome study
    Magnus Olivecrona
    Department of Neurosurgery, Umea University Hospital, Umea, Sweden
    J Neurotrauma 26:1251-62. 2009
    ..This study is a prospective consecutive double-blinded randomized study on the effect of PGI(2) versus placebo in severe traumatic brain injury (sTBI). All patients with sTBI were eligible...
  52. ncbi Prostacyclin signaling regulates circulating ghrelin during acute inflammation
    Lisa D Madison
    Department of Pediatrics Neuroscience Graduate Program, Oregon Health and Science University, Portland, Oregon, USA
    J Endocrinol 196:263-73. 2008
    ..These data provide further support for the potential role of ghrelin as a therapeutic agent in acute and chronic inflammatory diseases...
  53. ncbi Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol
    Karl P Kuhn
    Center for Lung Research, Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 2650, USA
    Am J Respir Crit Care Med 167:580-6. 2003
    b>Epoprostenol has markedly improved the treatment of pulmonary arterial hypertension, although predictors of outcome with epoprostenol are not well characterized...
  54. pmc Long-term effects of epoprostenol on the pulmonary vasculature in idiopathic pulmonary arterial hypertension
    Stuart Rich
    Department of Medicine, University of Chicago, Section of Cardiology, 5841 S Maryland Ave, Ste LO 8 MC 5403, Chicago, IL 60637, USA
    Chest 138:1234-9. 2010
    ..We report the autopsy findings from a patient with idiopathic PAH treated with epoprostenol successfully for 18 years. The patient died of colon cancer...
  55. ncbi Increased [18F]fluorodeoxyglucose accumulation in right ventricular free wall in patients with pulmonary hypertension and the effect of epoprostenol
    Minako Oikawa
    Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan
    J Am Coll Cardiol 45:1849-55. 2005
    ..ventricular (RV) [(18)F]fluorodeoxyglucose (FDG) accumulation is increased in patients with pulmonary hypertension using gated positron emission tomography (PET) and whether RV FDG accumulation changes after therapy with epoprostenol.
  56. pmc Prostacyclin prevents pulmonary endothelial cell apoptosis induced by cigarette smoke
    S Patrick Nana-Sinkam
    The Ohio State University, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, 201 Davis Heart and Lung Research Institute, 473 West 12th Avenue, Columbus, OH 43210, USA
    Am J Respir Crit Care Med 175:676-85. 2007
    ..Prostacyclin (PGI(2)) is a major product of the cyclooxygenase pathway with potent vasodilatory and antimitogenic properties and may be relevant to endothelial dysfunction in COPD...
  57. ncbi cDNA cloning of a mouse prostacyclin receptor. Multiple signaling pathways and expression in thymic medulla
    T Namba
    Department of Pharmacology, Faculty of Medicine, Kyoto University, Japan
    J Biol Chem 269:9986-92. 1994
    ..Northern blot analysis revealed that the mRNA is expressed most abundantly in thymus, followed by spleen, heart, and lung. In situ hybridization of thymus showed that it is expressed exclusively in medulla and not in cortex...
  58. ncbi Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis
    H Olschewski
    Depatment of Internal Medicine II, Justus Liebig University, Giessen, Germany
    Am J Respir Crit Care Med 160:600-7. 1999
    ..Long-term therapy with inhaled iloprost may be life saving in decompensated right heart failure from pulmonary hypertension secondary to lung fibrosis...
  59. ncbi Prostacylin receptor activation inhibits proliferation of aortic smooth muscle cells by regulating cAMP response element-binding protein- and pocket protein-dependent cyclin a gene expression
    Devashish Kothapalli
    Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 6084, USA
    Mol Pharmacol 64:249-58. 2003
    ..We conclude that PGI2 inhibits proliferation of aortic smooth muscle cells by coordinately blocking CRE- and pocket protein-dependent cyclin A gene expression...
  60. ncbi Prostaglandin I2 analogs inhibit Th1 and Th2 effector cytokine production by CD4 T cells
    Weisong Zhou
    Department of Medicine, Division of Allergy, Pulmonary and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN 37232 2650, USA
    J Leukoc Biol 81:809-17. 2007
    ..These data indicate that PGI(2) analogs have an immune-suppressive effect on previously activated and differentiated CD4 T cells in vitro and suggest that PGI(2) may have a similar function in vivo...
  61. pmc RO1138452 and RO3244794: characterization of structurally distinct, potent and selective IP (prostacyclin) receptor antagonists
    Keith R Bley
    Roche Palo Alto, Palo Alto, CA 94304, USA
    Br J Pharmacol 147:335-45. 2006
    ..These data suggest that RO1138452 and RO3244794 are potent and selective antagonists for both human and rat IP receptors and that they possess analgesic and anti-inflammatory potential...
  62. pmc Signaling through the prostaglandin I2 receptor IP protects against respiratory syncytial virus-induced illness
    Koichi Hashimoto
    Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA
    J Virol 78:10303-9. 2004
    ..These results suggest that signaling through IP has antiviral effects while protecting against RSV-induced illness and that PGI(2) is a potential therapeutic target in the treatment of RSV...
  63. ncbi Survival in primary pulmonary hypertension: the impact of epoprostenol therapy
    Vallerie V McLaughlin
    Rush Presbyterian St Luke s Medical Center, Department of Medicine, Section of Cardiology, Chicago, Ill 60612, USA
    Circulation 106:1477-82. 2002
    ..8 years, with survival rates of 68%, 48%, and 34% at 1, 3, and 5 years, respectively. Intravenous epoprostenol was the first Food and Drug Administration-approved therapy for PPH...
  64. ncbi Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension
    Mardi Gomberg-Maitland
    Pulmonary Hypertension Center, University of Chicago Hospitals, 5841 South Maryland Avenue, MC 2016, Chicago, IL 60637, USA
    Am J Respir Crit Care Med 172:1586-9. 2005
    Intravenous epoprostenol improves exercise capacity and survival in patients with pulmonary arterial hypertension...
  65. ncbi Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial
    Gerald Simonneau
    Service de Pneumologie, Hopital Antoine Beclere, Universite Paris Sud, Clamart, France
    Ann Intern Med 149:521-30. 2008
    Oral sildenafil and intravenous epoprostenol have independently been shown to be effective in patients with pulmonary arterial hypertension.
  66. pmc Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets
    M W Radomski
    Wellcome Research Laboratories, Beckenham, Kent
    Br J Pharmacol 92:181-7. 1987
    ..6 It is likely that the inhibitory effect of NO on platelets represents the action of endogenous EDRF and therefore this substance, together with prostacyclin, is a regulator of platelet-vessel wall interactions...
  67. ncbi Altered pain perception and inflammatory response in mice lacking prostacyclin receptor
    T Murata
    Department of Pharmacology, Faculty of Medicine, Kyoto University, Sakyo, Japan
    Nature 388:678-82. 1997
    ..Our results establish that prostacyclin is an antithrombotic agent in vivo and provide evidence for its role as a mediator of inflammation and pain...
  68. ncbi Molecular mechanisms of the antiproliferative effect of beraprost, a prostacyclin agonist, in murine vascular smooth muscle cells
    Heng Lin
    Institute of Pharmacology and Toxicology, Tzu Chi University, Hualien, Taiwan
    J Cell Physiol 214:434-41. 2008
    ..Taken together, the results suggest that the causal relationship between PPARdelta and iNOS contributes to the vasoprotective action of beraprost in RASMCs...
  69. pmc Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension
    Emilia Falcetti
    Department of Medicine, UCL, London, United Kingdom
    Am J Respir Crit Care Med 182:1161-70. 2010
    ....
  70. ncbi A novel pathway of prostacyclin signaling-hanging out with nuclear receptors
    Hyunjung Lim
    Department of Obstetrics and Gynecology, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Endocrinology 143:3207-10. 2002
    ..This review attempts to cover recent developments in nuclear actions of PGI(2) in diverse biological functions...
  71. ncbi Role of prostaglandin I2 in airway remodeling induced by repeated allergen challenge in mice
    Koichi Nagao
    Department of Pharmacology, Gifu Pharmaceutical University, Japan
    Am J Respir Cell Mol Biol 29:314-20. 2003
    ....
  72. ncbi Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment
    Kimberly A Fisher
    Pulmonary Center, Boston University School of Medicine, Boston, MA, USA
    Chest 130:1481-8. 2006
    ..Pulmonary hypertension is a known complication of sarcoidosis and is associated with increased mortality. Little is known about the outcome of sarcoidosis-associated pulmonary hypertension, including response to treatment...
  73. pmc Augmentation of allergic inflammation in prostanoid IP receptor deficient mice
    Yoshimasa Takahashi
    Department of Pharmacology, Gifu Pharmaceutical University, 5 6 1 Mitahora Higashi, Gifu 502 8585, Japan
    Br J Pharmacol 137:315-22. 2002
    ..These findings suggest a regulatory role of PGI(2) in allergic inflammation...
  74. ncbi Micrococcus-associated central venous catheter infection in patients with pulmonary arterial hypertension
    Ronald J Oudiz
    Division of Cardiology, Research and Education Institute, Harbor UCLA Medical Center, Torrance, CA 90502, USA
    Chest 126:90-4. 2004
    ..the incidence of catheter-related infection in patients with pulmonary arterial hypertension (PAH) receiving epoprostenol (EPO), and to note an etiologic role for Micrococcus spp, which is rarely reported as a pathogen in the medical ..
  75. ncbi Stability and preservative effectiveness of treprostinil sodium after dilution in common intravenous diluents
    Kenneth R Phares
    United Therapeutics Corporation, 68 T W Alexander Drive, Research Triangle Park, NC 27709, USA
    Am J Health Syst Pharm 60:916-22. 2003
    ..Treprostinil sodium 0.004 mg/mL in sterile water and 0.9% sodium chloride for injection and 0.02 mg/mL in 5% dextrose injection was also stable under the same conditions. None of the solutions showed signs of microbial growth...
  76. ncbi Coxibs and cardiovascular disease
    Garret A Fitzgerald
    Institute for Translational Medicine and Therapeutics, University of Pennsylvania, Philadelphia, USA
    N Engl J Med 351:1709-11. 2004
  77. ncbi Effect of enhanced prostacyclin synthesis by adenovirus-mediated transfer on lipopolysaccharide stimulation in neuron-glia cultures
    May Jywan Tsai
    Neural Regeneration Laboratory, Department of Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Shih Pai Road, Sec 2, Taipei, Taiwan 11217
    Ann N Y Acad Sci 1042:338-48. 2005
    ..Taken together, enhanced prostacyclin synthesis in neuron-glial cultures reduced microglia number and suppressed LPS stimulation...
  78. ncbi Treatment of pulmonary arterial hypertension: the role of prostacyclin and prostaglandin analogs
    Zeenat Safdar
    Baylor College of Medicine, 6620 Main Street, Suite 11B 09, Houston, TX 77030, USA
    Respir Med 105:818-27. 2011
    ..This review discusses the pharmacology, clinical effects, and routes of administration of prostacyclin and prostaglandin analogs, emphasizing the advantages and disadvantages of each from the clinical perspective...
  79. pmc Cell-type- and cell-cycle-specific anti-mitogenesis by cicaprost
    Paola Castagnino
    Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 6084, United States
    Prostaglandins Other Lipid Mediat 93:20-4. 2010
    ..We conclude that stable PGI(2) mimetics may be highly specific inhibitors of p27(kip1)-dependent VSMC proliferation after vascular injury...
  80. ncbi Prostaglandin I2 (epoprostenol) triggers migraine-like attacks in migraineurs
    T Wienecke
    Department of Neurology, Glostrup Hospital, Faculty of Health Sciences, University of Copenhagen, Danish Headache Centre, Glostrup, Copenhagen, Denmark
    Cephalalgia 30:179-90. 2010
    ..We hypothesized that intravenous infusion of the stable prostacyclin analogue epoprostenol would trigger migraine-like attacks in migraineurs...
  81. ncbi Amelioration of diabetic nephropathy in OLETF rats by prostaglandin I(2) analog, beraprost sodium
    Maho Watanabe
    Division of Nephrology and Rheumatology, Department of Internal Medicine, Faculty of Medicine, Fukuoka University, Jonan ku, Fukuoka, Japan
    Am J Nephrol 30:1-11. 2009
    ..The present study aimed to examine whether the prostaglandin I(2) analog beraprost sodium (BPS) ameliorates diabetic nephropathy in Otsuka Long-Evans Tokushima Fatty (OLETF) rat...
  82. ncbi Treprostinil for the treatment of pulmonary hypertension
    Nika Skoro-Sajer
    Medical University of Vienna, Division of Cardiology, Department of Internal Medicine II, Waehringer Guertel 18 20, 1090 Vienna, Austria
    Expert Opin Pharmacother 9:1415-20. 2008
    ....
  83. ncbi Subcutaneous implantation of a new intravenous pump system for prostacyclin treatment in patients with pulmonary arterial hypertension
    Susanna Desole
    Pneumology University Specialized Center for Pulmonary Hypertension Innsbruck, Internal Medicine I, Department of Internal Medicine, Innsbruck Medical University, Innsbruck, Austria
    Heart Lung 41:599-605. 2012
    ..However, intravenous prostacyclin treatment involves several limitations, because the available battery-driven pump systems carry the risk of line infections, catheter-related embolisms, thrombosis, and delivery system malfunctions...
  84. ncbi Low-dose prostacyclin in treatment of severe brain trauma evaluated with microdialysis and jugular bulb oxygen measurements
    P O Grande
    Department of Anaesthesia and Intensive Care, University Hospital of Lund, Sweden
    Acta Anaesthesiol Scand 44:886-94. 2000
    ....
  85. ncbi Regulation of cytokine expression in human plasmacytoid dendritic cells by prostaglandin I2 analogues
    C H Hung
    Dept of Paediatrics, Kaohsiung Medical University Hospital, No 100, Tz You 1st Road, Kaohsiung 807, Taiwan
    Eur Respir J 33:405-10. 2009
    ....
  86. ncbi COX-2-derived prostacyclin protects against bleomycin-induced pulmonary fibrosis
    Alysia Kern Lovgren
    Curriculum in Genetics and Molecular Biology, University of North Carolina at Chapel Hill, 27599, USA
    Am J Physiol Lung Cell Mol Physiol 291:L144-56. 2006
    ..If such protection is observed, investigation of these agents as a novel therapeutic approach to pulmonary fibrosis in humans may be warranted...
  87. ncbi A synthetic small molecule, ONO-1301, enhances endogenous growth factor expression and augments angiogenesis in the ischaemic heart
    Kazuto Nakamura
    Department of Cardiovascular Medicine, University of Tokyo Graduate School of Medicine, Hongo, Bunkyo ku, Tokyo, Japan
    Clin Sci (Lond) 112:607-16. 2007
    ..In conclusion, our results indicate that ONO-1301 up-regulated endogenous growth factors and promoted angiogenesis in response to acute ischaemia. Therefore ONO-1301 might have a therapeutic potential in treating ischaemic diseases...
  88. pmc Rapid transition from inhaled iloprost to inhaled treprostinil in patients with pulmonary arterial hypertension
    Robert C Bourge
    University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Cardiovasc Ther 31:38-44. 2013
    ....
  89. ncbi Protection of endothelial survival by peroxisome proliferator-activated receptor-delta mediated 14-3-3 upregulation
    Jun Yang Liou
    Vascular Biology Research Center, Brown Foundation Institute of Molecular Medicine, Houston, TX 77030 1503, USA
    Arterioscler Thromb Vasc Biol 26:1481-7. 2006
    ..To determine the role of prostacyclin (PGI2) in protecting endothelial cells (ECs) from apoptosis and elucidate the protective mechanism...
  90. ncbi Endothelial mediators of the acetylcholine-induced relaxation of the rat femoral artery
    Hok Sum Leung
    Li Ka Shing Institute of Health Sciences and Department of Physiology, Chinese University of Hong Kong, Shatin, NT, Hong Kong SAR, China
    Vascul Pharmacol 44:299-308. 2006
    ..Thus, the eNOS-dependent H2O2 is likely to be the third mediator of acetylcholine-mediated relaxations in rat femoral arteries...
  91. ncbi Epoprostenol inhibits human platelet-leukocyte mixed conjugate and platelet microparticle formation in whole blood
    Chiara Tamburrelli
    Laboratory of Cell Biology and Pharmacology of Thrombosis, Research Laboratories, Center for High Technology Research and Education in Biomedical Sciences John Paul II, Catholic University, Campobasso, Italy
    Thromb Res 128:446-51. 2011
    ..b>Epoprostenol is a synthetic salt of PGI2 (prostacyclin) clinically used in pulmonary hypertension and transplantation as a ..
  92. ncbi The experiences of patients with pulmonary arterial hypertension receiving continuous intravenous infusion of epoprostenol (Flolan) and their support persons
    Heather Hall
    Jewish General Hospital, School of Nursing, McGill University, Montreal, Quebec, Canada
    Heart Lung 41:35-43. 2012
    Little is known about the day-to-day experiences of patients and their support persons during the course of epoprostenol treatment for pulmonary arterial hypertension (PAH)...
  93. ncbi Cytochrome P-450 metabolites but not NO, PGI2, and H2O2 contribute to ACh-induced hyperpolarization of pressurized canine coronary microvessels
    Mitsuaki Tanaka
    Department of Comprehensive Medicine, Tohoku University School of Medicine, 1 1 Seiryo machi, Aobaku, Sendai 980 8574, Japan
    Am J Physiol Heart Circ Physiol 285:H1939-48. 2003
    ....
  94. ncbi Prostacyclin infusion may prevent secondary damage in pericontusional brain tissue
    Peter Reinstrup
    Department of Intensive and Perioperative Care, Lund University Hospital, Lund, Sweden
    Neurocrit Care 14:441-6. 2011
    ..When biochemical signs of cerebral ischemia progressed, i.v. infusion of prostacyclin was started...
  95. ncbi Effects of PGI2 analogues on Th1- and Th2-related chemokines in monocytes via epigenetic regulation
    Chang Hung Kuo
    Department of Pediatrics, Kaohsiung Municipal Ta Tung Hospital, Kaohsiung, Taiwan, Republic of China
    J Mol Med (Berl) 89:29-41. 2011
    ..PGI(2) analogues may therefore increase Th2 recruitment and inflammation...
  96. ncbi Selexipag: a selective prostacyclin receptor agonist that does not affect rat gastric function
    Keith Morrison
    Drug Discovery Department, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
    J Pharmacol Exp Ther 335:249-55. 2010
    ..The high functional selectivity of selexipag and ACT-333679 for the IP receptor precludes a stimulatory action on gastric smooth muscle and may help minimize gastric side effects such as nausea and vomiting...
  97. ncbi Lack of a pharmacokinetic interaction between oral treprostinil and bosentan in healthy adult volunteers
    S Karl Gotzkowsky
    United Therapeutics Corporation, 55 T W Alexander Drive, PO Box 14186, Research Triangle Park, NC 27709, USA
    J Clin Pharmacol 50:829-34. 2010
    ..06) and 1.03 (0.94, 1.13). In conclusion, because the GMR and 90% CI are within the equivalence interval of 0.8 to 1.25, co-administration of oral treprostinil and bosentan did not result in a pharmacokinetic interaction for either agent...
  98. ncbi New insights into the intracellular mechanisms by which PGI2 analogues elicit vascular relaxation: cyclic AMP-independent, Gs-protein mediated-activation of MaxiK channel
    Yoshio Tanaka
    Department of Chemical Pharmacology, Toho University School of Pharmaceutical Sciences, 2 2 1 Miyama, Funabashi City, Chiba 274 8510, Japan
    Curr Med Chem Cardiovasc Hematol Agents 2:257-65. 2004
    ..Our recent work demonstrates a functional tight coupling between IPR and MaxiK channel through a cAMP-independent, G(s)-protein mediated mechanism(s) in vascular smooth muscle...
  99. ncbi Retinoic acid induces PGI synthase expression in human endothelial cells
    Mercedes Camacho
    Angiology, Vascular Biology, and Inflammation Laboratory of the Institute of Research, Hospital Santa Creu i Sant Pau, Barcelona, Spain
    J Lipid Res 49:1707-14. 2008
    ..These results reinforce the concept that RA could be beneficial for patients with cardiovascular risk...
  100. pmc Prostacyclin analogs inhibit fibroblast contraction of collagen gels through the cAMP-PKA pathway
    Koichiro Kamio
    University of Nebraska Medical Center, 985885 Nebraska Medical Center, Omaha, NE 68198 5885, USA
    Am J Respir Cell Mol Biol 37:113-20. 2007
    ..The ability of prostacyclin to modulate fibroblast function suggests that prostacyclin can contribute to tissue remodeling...
  101. ncbi Increased cortical cell loss and prolonged hemodynamic depression after traumatic brain injury in mice lacking the IP receptor for prostacyclin
    Cornelia Lundblad
    Department of Anesthesiology and Intensive Care, University of Lund and Lund University Hospital, Lund, Sweden
    J Cereb Blood Flow Metab 28:367-76. 2008
    ..We conclude that the prostacyclin IP receptor is beneficial for neuron survival after brain trauma in mice, an effect that may be mediated by improved cortical perfusion...

Research Grants62

  1. PPAR gamma Agonists for Lung Cancer Chemoprevention
    Robert Keith; Fiscal Year: 2013
    ..Our results will lead to a better understanding of the early stages of lung cancer and may lead to future human chemoprevention trials. ..
  2. Endothelial Lipoxygenase Metabolites and Vascular Tone
    WILLIAM BRYSON CAMPBELL; Fiscal Year: 2013
    ..These studies will identify two new mechanisms of action for the endothelium-derived relaxing factor 11,12,15-THETA and provide a new therapeutic approach to enhancing endothelial function. ..
  3. Mechanobiology of Vascular Remodeling in Pulmonary Arterial Hypertension
    LAURA ELIZABETH FREDENBURGH; Fiscal Year: 2013
    ....
  4. Arterial Stiffness in the Pathogenesis of Human Pulmonary Arterial Hypertension
    LAURA ELIZABETH FREDENBURGH; Fiscal Year: 2013
    ....
  5. Anti-PAH Drugs in Inhalable Nanoparticles for Sustained Pulmonary Vasodilation
    Fakhrul Ahsan; Fiscal Year: 2010
    ..collapse due to interruption of infusion are the potentially serious complications of PAH therapy with epoprostenol and treprostinil...
  6. The Role of PGI2 in Allergic Inflammation
    Ray Stokes Peebles; Fiscal Year: 2013
    ..Therefore, defining the role of PGI2 and its cellular receptor in allergic inflammation in vivo might result in novel targets for drug development in this important disease. ..
  7. THE TREATMENT OF PULMONARY HYPERTENSION
    James Pachence; Fiscal Year: 2000
    ..General vasodilators such as hydralazine and the prostacyclin analogue epoprostenol have been used, but are only marginally effective...
  8. PGI & TXA SYNTHASES--MEMBRANE ANCHOR STRUCTURE/FUNCTION
    Ke He Ruan; Fiscal Year: 1999
    ..Comparisons can then be made between the membrane anchor structure of these two eicosanoid-forming P450s and the anchor structures of other microsomal P450s. ..
  9. ROLE OF C-AMP IN RENIN RELEASE
    WINFRED MAGEE; Fiscal Year: 1990
    ..Data on renin release and cyclic adenosine monophosphate production as determined by radioimmunoassay on a cell culture system enriched in juxtaglomerular cells will be evaluated...
  10. Mentored Patient-Oriented Research Career Development Aw
    IVAN ROBBINS; Fiscal Year: 2004
    ..Over the past decade, intravenous epoprostenol, the synthetic analogue of prostacyclin, has emerged as the most effective treatment of PPH...
  11. REGULATION OF ENDOTHELIAL CELL PHOSPHOLIPASES A2 AND C
    Thomas Martin; Fiscal Year: 1990
    ..Specific antisera to these proteins are investigated for their ability to reverse or attenuate glucocorticoid effects...
  12. Nitric Oxide/Carbon Monoxide in Pulmonary Hypertention
    Raed Dweik; Fiscal Year: 2006
    ..As an extension of this hypothesis, we also propose that effective therapies such as epoprostenol, may act in part by increasing NO levels in PPH...
  13. ROLE OF ENDOTHELIN IN PERINATAL PULMONARY VASOREGULATION
    DAVID IVY; Fiscal Year: 2002
    ..Research presentations along with graduate level courses in molecular biology, and the clinical ambiance of the Univ of CO SOM in the area of pulmonary hypertension enhance career development. ..
  14. Prostaglandin I synthase, Thromboxane A synthase & Prostaglandin E synthase
    Ke He Ruan; Fiscal Year: 2009
    ....
  15. STRUCTURE & FUNCTION RELATIONSHIP: PROSTANOID RECEPTORS
    Ke He Ruan; Fiscal Year: 2008
    ..Determine the solution conformation of segments comprising the intracellular domains. ..
  16. RELATIVE ARGININE DEFICIENCY IN PULMONARY HYPERTENSION
    David Badesch; Fiscal Year: 2004
    ..abstract_text> ..
  17. Cardiopulmonary Exercise Testing: Pulmonary Hypertension
    Ronald Oudiz; Fiscal Year: 2007
    .._l.Center. PHS 398/2590(Rev.05/01) Page _, LJ ContinuationFormatPage NumberpagesconsecutivelyatthebottomthroughoutheapplicationD. o no_u_stesuffixesuchas3a, 3b. ..
  18. Oxidative Modifications in Atherogenesis
    Garret FitzGerald; Fiscal Year: 2006
    ..abstract_text> ..
  19. Protective Efficacy of Mg-Supplementation Against NRTI-induced Cardiac Toxicity
    IVAN MAK; Fiscal Year: 2007
    ..This proposed exploratory effort may reveal a potential usefulness of Mg-supplements as an effective, yet relatively inexpensive adjunct therapy to lessen NRTI-related cardiovascular toxicity. ..
  20. ACTION - A CHF Trial Investigating Outcomes of Exercise
    CHRISTOPHER O CONNOR; Fiscal Year: 2008
    ..The trial will take place over 5 years with an initial 6 months for planning, training, and implementation; 3 years of enrollment; 1 year of follow-up; and 6 months for close out, analysis, and presentation. ..
  21. PROSPECTIVE INVESTIGATION OF PULMONARY EMBOLISM DX-II
    Victor Tapson; Fiscal Year: 2003
    ..abstract_text> ..
  22. GENETIC DETERMINATION OF ALLOGRAFT VASCULOPATHY
    Raymond Benza; Fiscal Year: 2002
    ..If his faculty mentor were to leave the institution, a new mentor will be appointed and his continued development toward becoming a independent physician scientist supported and encouraged. ..
  23. Pharmacogenomics in Pulmonary Arterial Hypertension
    Raymond Benza; Fiscal Year: 2008
    ..PAH = pulmonary arterial hypertension PA = pulmonary artery PPH = primary pulmonary hypertension ..
  24. Nicotine and Chronic Kidney Disease
    Edgar A Jaimes; Fiscal Year: 2010
    ..We will use a variety of state of the art techniques to assess the mechanisms by which nicotine induces renal injury. ..
  25. Oxidative stress, Homocysteine and Alzheimer's Disease
    Domenico Pratico; Fiscal Year: 2008
    ..These studies will be a necessary basis before prevention studies aimed to reduce Hcy levels are initiated in patients at risk for AD. ..
  26. Regulation of Prostacyclin in Pulmonary Hypertension
    SERGE NANA SINKAM; Fiscal Year: 2008
    ..abstract_text> ..
  27. EDHF in the Cerebral Circulation
    ROBERT BRYAN; Fiscal Year: 2009
    ..Furthermore, we anticipate that new information regarding tandem pore domain potassium channels will be a big step in the understanding of cerebral circulatory control. ..
  28. PLACENTAL FUNCTION IN PREECLAMPSIA
    Yuping Wang; Fiscal Year: 2009
    ..Results obtained from the proposed work should enhance our knowledge and establish a direct link of placental TC activity and EC dysfunction in PE. ..
  29. Mast Cell-Induced Inflammation in Vascular Disease
    Kottarappat N Dileepan; Fiscal Year: 2010
    ..abstract_text> ..
  30. Proatherogenic properties of platelet fator 4
    Bruce S Sachais; Fiscal Year: 2010
    ..into the role of PF4, the most abundant protein released by activated platelets, on the development of atherosclerosis, delineate the pathways by which this occurs in vivo, and suggest potential methods to intervene in atherogenesis ..
  31. ENDOTHELIAL BARRIER FUNCTION IN PREECLAMPSIA
    Yuping Wang; Fiscal Year: 2010
    ..The influence of CLP on placental sFlt-1 will be studied. Results obtained from the proposed work should enhance current knowledge of the role of the placenta and EC dysfunction in the pathogenesis of PE. ..
  32. Tetrahydrobiopterin: Regulator of Endothelial Function
    ZVONIMIR KATUSIC; Fiscal Year: 2009
    ..This information may help to develop new strategies in prevention and treatment of endothelial dysfunction. . ..
  33. Role of ANG II in Maintaining Vascular Relaxation in Dahl S Rats
    Julian H Lombard; Fiscal Year: 2010
    ..abstract_text> ..
  34. EICOSANOIDS, VASCULAR TONE AND BLOOD PRESSURE
    WILLIAM BRYSON CAMPBELL; Fiscal Year: 2010
    ..These studies will test the hypothesis that endogenous LO metabolites are important regulators of vascular tone and blood pressure in mice. ..
  35. 8th World Congress for Microcirculation
    JULIAN LOMBARD; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  36. Mechanochemical regulation of endothelial permeability
    Konstantin Birukov; Fiscal Year: 2007
    ....
  37. CEREBAL ARTERIAL ADVENTITIA AND VASOSPASM
    ZVONIMIR KATUSIC; Fiscal Year: 2001
    ..Our studies will also expand the knowledge base concerning the vascular biology of adventitia, and its role as a target for transfer and expression of therapeutically beneficial recombinant proteins. ..
  38. Nitric Oxide-Superoxide in Lipid Induced Vascular Diseas
    ZVONIMIR KATUSIC; Fiscal Year: 2005
    ....
  39. Nitric Oxide Regulation of Adrenal Steroidogenesis
    William Campbell; Fiscal Year: 2004
    ..4) We will determine the role of endothelial NO in regulating steroidogenesis and adrenal blood flow in the in situ perfused adrenal gland and in vivo in anesthetized rats. ..
  40. Role of Erythrocytes in Circulatory Control
    Randy Sprague; Fiscal Year: 2004
    ..abstract_text> ..
  41. Drugs targeting intact lipoprotein receptors
    BRUCE SACHAIS; Fiscal Year: 2004
    ..Specific Aim 2: Create and validate biosensor-based analysis of LDL-R lipoparticles. In this aim, we will use LDL-R lipoparticles on the optical biosensor platform with the goal of measuring ligand-binding kinetics. ..
  42. CARDIAC VALVE CALCIFICATION
    Emile Mohler; Fiscal Year: 2003
    ..2. To investigate mechanisms of valve calcification using a cell culture model of calcification. 3. To examine therapeutic strategies to inhibit valve calcification with a bisphosphonate in cell culture. ..
  43. CYTOCHROME P450 EICOSANOIDS AND PULMONARY HEMODYNAMICS
    Alan Stephenson; Fiscal Year: 2002
    ..abstract_text> ..
  44. PO2 MODULATION OF NO AND ET1 IN PULMONARY HYPERTENSION
    Karen Fagan; Fiscal Year: 2002
    ..Improved understanding of these endogenous vasoregulatory substances, their interactions with one another, and the effect of modest hypoxia in vivo are the major goals of this proposal and may lead to new therapeutic options. ..
  45. MECHANISMS OF PROSTAGLANDIN INDUCED INTESTINAL REPAIR
    Anthony Blikslager; Fiscal Year: 2002
    ..These experiments will provide insight into the signaling pathways and mechanisms by which prostaglandins trigger repair of acutely-injured intestinal epithelium. ..
  46. MECHANISMS OF ALTERED VASOREACTIVITY IN SCLERODERMA
    NICHOLAS FLAVAHAN; Fiscal Year: 2002
    ..These studies should increase our understanding of the SSc disease process and may provide a scientific basis for therapeutic intervention. ..
  47. Discovery of biomarkers of pulmonary hypertension
    Rubin Tuder; Fiscal Year: 2005
    ..abstract_text> ..
  48. The Erythrocyte: a Regulator of Microvascular Perfusion
    Mary Ellsworth; Fiscal Year: 2005
    ..abstract_text> ..
  49. Il-6 type cytokine protection from hyperoxic lung injury
    Aaron Waxman; Fiscal Year: 2007
    ..abstract_text> ..
  50. Neurohormonal Activation in Pulmonary Hypertension
    Steven Kawut; Fiscal Year: 2005
    ..We will formulate prediction rules using neurohormone levels and clinical variables to improve prognostication and management in this disease. ..
  51. Effects of BMPRII Mutations in Pulmonary Hypertension
    Karen Fagan; Fiscal Year: 2006
    ..We will have also tested the role of four pulmonary cell types, smooth muscle, endothelium, airway epithelium and macrophages in the link between BMPR2 and pulmonary hypertension. ..
  52. Genetics of Pulmonary Hypertension in Mice
    Karen Fagan; Fiscal Year: 2006
    ..abstract_text> ..
  53. The Role of Central Melanocortins in Cachexia
    Daniel Marks; Fiscal Year: 2006
    ..Ultimately, this work may lead to investigation of drug therapy for this widespread medical problem. ..
  54. Regulation of Nuclear Import/Export of 5-Lipoxygenase
    Thomas Brock; Fiscal Year: 2006
    ..This foundation can then be used to elucidate the ways these factors can change and give rise to the disease states that arise from abnormal 5-LO localization and LT synthesis. ..
  55. Pulmonary Arterial Hypertension: Avian Model of Complex Vascular Lesion Developme
    ROBERT WIDEMAN; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  56. Cognitive dysfunction in neuropsychiatric-SLE
    Michael Lockshin; Fiscal Year: 2002
    ..Successful completion of this research will redefine the pathogenesis of cognitive dysfunction and suggest therapeutic targets for intervention...
  57. LC-MS/MS for Biomedical Research
    William Campbell; Fiscal Year: 2004
    ..About 75-80% of instrument time will be available to these participants and the remaining time will be available to other investigators at the College. ..
  58. ETHANOL SENSITIVITY OF NATIVE AND CLONED NMDA RECEPTORS
    John Woodward; Fiscal Year: 2009
    ..Aim 3 will express ethanol-insensitive receptors identified in Aims 1 and 2 in neurons in vitro and in vivo to address which effects of ethanol are mediated by inhibition of NMDA receptors. ..
  59. The neurobiology of 12/15 lipoxygenase
    Domenico Pratico; Fiscal Year: 2007
    ..Such data are clinically relevant and should provide important clues to the potential use of specific 12/15LO inhibitors as novel therapeutic agents for preventing or limiting the evolution and/or progression of AD. ..
  60. NO& Epithelial Repair in Cryptosporidiosis
    Jody Gookin; Fiscal Year: 2006
    ..abstract_text> ..
  61. Mechanisms of Vascular Dysfunction in Vibration Injury
    NICHOLAS FLAVAHAN; Fiscal Year: 2009
    ..2 will determine mechanisms underlyingthe vibration-induced increase in cold sensitivity of cutaneous arteries;and Aim 3 will determine the effects of vibration on endothelial cell function and vascular structure ..
  62. Redox Regulation of Arteriole Function
    NICHOLAS FLAVAHAN; Fiscal Year: 2005
    ..Experiments will assess the stimuli responsible for ROS production, the mechanisms underlying ROS-induced changes in vasoconstriction and the regulation of this signaling pathway in hypertension. ..